Gastrointestinal Cancer News

Surefire Medical released results of a retrospective study of bridge-to-transplant patients with hepatocellular carcinoma treated with transarterial chemoembolization, or DEB-TACE, that showed a higher complete response rate using the Surefire Infusion System compared with standard endhole microcatheter, according to a press release.

CHICAGO — Results of a phase 3 trial showed that Lenvima was non-inferior to Nexavar in median overall survival for patients with unresectable hepatocellular carcinoma, according to a presentation at the ASCO Annual Meeting.

Pathologists are often over-diagnosing cases of low-grade appendiceal mucinous neoplasm as invasive appendiceal adenocarcinoma, according to recent study data.

CHICAGO — Epacadostat in combination with nivolumab appeared safe and effective in patients with advanced melanoma and head and neck cancer, according to preliminary data from the ECHO-204 trial presented at the ASCO Annual Meeting.

Foundation Medicine, NCI and ECOG-ACRIN Cancer Research Group entered a collaboration to evaluate the benefit of genomically guided treatments targeting specific alterations within a patient’s tumor, regardless of cancer type.

Exposure to air pollution with particulate matter over 2.5 m in diameter, or PM2.5, after diagnosis of hepatocellular carcinoma had adverse effects in patients and may shorten overall survival, according to a retrospective study.

Only one in 30 patients with cancer enroll in clinical trials.

New data revealed an association between postmenopausal estrogen use and a reduced risk for hepatocellular carcinoma and increased overall survival time in women with HCC.

CHICAGO — The addition of PEGPH20 to chemotherapy significantly prolonged PFS among patients with untreated metastatic pancreatic ductal adenocarcinoma, according to randomized study results presented at the ASCO Annual Meeting.

CHICAGO — Nivolumab alone or in combination with ipilimumab demonstrated clinical activity in Western patients with chemotherapy-refractory esophagogastric cancer regardless of PD-L1 status, according to results of the CheckMate 032 study presented at the ASCO Annual Meeting.